Literature DB >> 25556583

Cancer chemoprevention: Much has been done, but there is still much to do. State of the art and possible new approaches.

Davide Serrano1, Matteo Lazzeroni1, Bernardo Bonanni2.   

Abstract

Over the past three decades great efforts have been made in search of cancer chemoprevention strategies. The increase in knowledge of the long process from normal to cancer cell has enabled interventions in terms of lifestyle modifications, natural compounds or drugs to block or reverse the process. Great successes have been achieved, especially for breast and colorectal cancer. However, these strategies have yet to find clinical application on a large scale. In this article we identify the achievements, the pitfalls and the next steps to be taken to improve the efficacy and applicability of chemoprevention strategies. Among the crucial key points to be implemented are educational activities for physicians to appropriately disseminate the aim and indeed the culture of chemoprevention. It is essential to improve the risk-benefit balance, seeking the minimal active doses, intermittent schedules, a better characterization of the risk categories via a more personalized intervention based on individual characteristics, and ensure the containment of costs of public and private health prevention programs.
Copyright © 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chemoprevention; Surrogate-biomarkers; Vaccines

Mesh:

Substances:

Year:  2014        PMID: 25556583      PMCID: PMC5528739          DOI: 10.1016/j.molonc.2014.12.006

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  81 in total

Review 1.  An intermittent approach for cancer chemoprevention.

Authors:  Xiangwei Wu; Scott M Lippman
Journal:  Nat Rev Cancer       Date:  2011-11-10       Impact factor: 60.716

Review 2.  How should we move the field of chemopreventive agent development forward in a productive manner?

Authors:  Frank Louis Meyskens; Eva Szabo
Journal:  Recent Results Cancer Res       Date:  2005

3.  Preventing cancer by targeting abnormally expressed self-antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas.

Authors:  Pamela L Beatty; Olivera J Finn
Journal:  Ann N Y Acad Sci       Date:  2013-05       Impact factor: 5.691

4.  Validation studies for models projecting the risk of invasive and total breast cancer incidence.

Authors:  J P Costantino; M H Gail; D Pee; S Anderson; C K Redmond; J Benichou; H S Wieand
Journal:  J Natl Cancer Inst       Date:  1999-09-15       Impact factor: 13.506

5.  Cancer chemoprevention and cancer preventive vaccines--a call to action: leaders of diverse stakeholder groups present strategies for overcoming multiple barriers to meet an urgent need.

Authors:  Ronald B Herberman; Homer L Pearce; Scott M Lippman; Bruce S Pyenson; David S Alberts
Journal:  Cancer Res       Date:  2006-12-07       Impact factor: 12.701

6.  Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.

Authors:  Jack Cuzick; John F Forbes; Ivana Sestak; Simon Cawthorn; Hisham Hamed; Kaija Holli; Anthony Howell
Journal:  J Natl Cancer Inst       Date:  2007-02-21       Impact factor: 13.506

7.  GC Glu416Asp and Thr420Lys polymorphisms contribute to gastrointestinal cancer susceptibility in a Chinese population.

Authors:  Liqing Zhou; Xiaojiao Zhang; Xuechao Chen; Li Liu; Chao Lu; Xiaohu Tang; Juan Shi; Meng Li; Mo Zhou; Zhouwei Zhang; Lingchen Xiao; Ming Yang
Journal:  Int J Clin Exp Med       Date:  2012-01-15

8.  A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers.

Authors:  Andrea Decensi; Chris Robertson; Giuseppe Viale; Francesca Pigatto; Harriet Johansson; Elton R Kisanga; Paolo Veronesi; Rosalba Torrisi; Massimiliano Cazzaniga; Serena Mora; Maria T Sandri; Giuseppe Pelosi; Alberto Luini; Aron Goldhirsch; Ernst A Lien; Umberto Veronesi
Journal:  J Natl Cancer Inst       Date:  2003-06-04       Impact factor: 13.506

Review 9.  Surrogate endpoint biomarkers for phase II cancer chemoprevention trials.

Authors:  G J Kelloff; C W Boone; J A Crowell; V E Steele; R Lubet; L A Doody
Journal:  J Cell Biochem Suppl       Date:  1994

10.  Multitargeted low-dose GLAD combination chemoprevention: a novel and promising approach to combat colon carcinogenesis.

Authors:  Altaf Mohammed; Naveena B Janakiram; Misty Brewer; Krishna Vedala; Vernon E Steele; Chinthalapally V Rao
Journal:  Neoplasia       Date:  2013-05       Impact factor: 5.715

View more
  9 in total

1.  Risk-reducing medications for primary breast cancer: a network meta-analysis.

Authors:  Simone Mocellin; Annabel Goodwin; Sandro Pasquali
Journal:  Cochrane Database Syst Rev       Date:  2019-04-29

Review 2.  Lessons learned from cancer prevention studies with nutrients and non-nutritive dietary constituents.

Authors:  Chung S Yang; Jayson X Chen; Hong Wang; Justin Lim
Journal:  Mol Nutr Food Res       Date:  2016-05-09       Impact factor: 5.914

Review 3.  Cancer chemoprevention: Much has been done, but there is still much to do. State of the art and possible new approaches.

Authors:  Davide Serrano; Matteo Lazzeroni; Bernardo Bonanni
Journal:  Mol Oncol       Date:  2014-12-20       Impact factor: 6.603

4.  The inhibiting activity of meadowsweet extract on neurocarcinogenesis induced transplacentally in rats by ethylnitrosourea.

Authors:  Vladimir G Bespalov; Valerij A Alexandrov; Galina I Vysochina; Vera А Kostikova; Denis A Baranenko
Journal:  J Neurooncol       Date:  2016-11-12       Impact factor: 4.130

5.  Emodin regulates neutrophil phenotypes to prevent hypercoagulation and lung carcinogenesis.

Authors:  Zibo Li; Yukun Lin; Shuhui Zhang; Lin Zhou; Guixi Yan; Yuehua Wang; Mengdi Zhang; Mengqi Wang; Haihong Lin; Qiaozhen Tong; Yongjian Duan; Gangjun Du
Journal:  J Transl Med       Date:  2019-03-18       Impact factor: 5.531

6.  Bioguided Fractionation of Local Plants against Matrix Metalloproteinase9 and Its Cytotoxicity against Breast Cancer Cell Models: In Silico and In Vitro Study.

Authors:  Maywan Hariono; Rollando Rollando; Jasson Karamoy; Pandu Hariyono; M Atmono; Maria Djohan; Wiwy Wiwy; Rina Nuwarda; Christopher Kurniawan; Nurul Salin; Habibah Wahab
Journal:  Molecules       Date:  2020-10-14       Impact factor: 4.411

Review 7.  The Promise of Preventive Cancer Vaccines.

Authors:  Pier-Luigi Lollini; Federica Cavallo; Patrizia Nanni; Elena Quaglino
Journal:  Vaccines (Basel)       Date:  2015-06-17

Review 8.  Chemoprevention of cancer: current evidence and future prospects.

Authors:  Vassiliki Benetou; Areti Lagiou; Pagona Lagiou
Journal:  F1000Res       Date:  2015-09-28

Review 9.  Leukoplakia and Immunology: New Chemoprevention Landscapes?

Authors:  Roberto Grigolato; Maria Eleonora Bizzoca; Luca Calabrese; Stefania Leuci; Michele Davide Mignogna; Lorenzo Lo Muzio
Journal:  Int J Mol Sci       Date:  2020-09-19       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.